As filed with the Securities and Exchange Commission on March 8, 2024
Registration No. 333-257264-01
Registration No. 333-264490-01
Registration No. 333-271005-01
Registration No. 333-271966-01
Registration No. 333-274952
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Post-Effective Amendment No. 2 to Registration Statement on Form S-8 (No. 333-257264-01)
Post-Effective Amendment No. 2 to Registration Statement on Form S-8 (No. 333-264490-01)
Post-Effective Amendment
No. 2 to Registration Statement on Form S-8 (No. 333-271005-01)
Post-Effective Amendment No. 2 to Registration Statement on Form S-8 (No. 333-271966-01)
Post-Effective Amendment No. 1 to Registration Statement on Form S-8 (No. 333-274952)
UNDER
THE SECURITIES ACT OF 1933
Ambrx
Biopharma, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
Delaware |
|
93-2892120 |
(State or other jurisdiction of
incorporation or organization) |
|
(I.R.S. Employer
Identification No.) |
10975 North Torrey Pines Road
La Jolla, California 92037
(Address of Principal Executive Offices, Including Zip Code)
Ambrx Biopharma, Inc. Second Amended and Restated 2016 Equity Incentive Plan
Ambrx Biopharma, Inc. Amended and Restated 2021 Equity Incentive Plan
Ambrx Biopharma, Inc. Amended and Restated 2021 Employee Share Purchase Plan
Share Options Granted as Employment Inducement Awards Outside of a Plan
Shares Granted as Compensation in Lieu of Cash
(Full title of the plan)
Sonja Nelson
Chief Financial Officer
Ambrx Biopharma, Inc.
10975 North Torrey Pines Road
La Jolla, California 92037
(Name and address of agent for service)
Telephone: (858) 875-2400
(Telephone number, including area code, of Agent for Service)
Copies to:
Robert I. Townsend, III
Ting S. Chen
Jin-Kyu Baek
Cravath, Swaine & Moore LLP
Worldwide Plaza
825
Eighth Avenue
New York, New York 10019
(212) 474-1000
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting
company, and emerging growth company in Rule 12b-2 of the Exchange Act.
|
|
|
|
|
|
|
Large accelerated filer |
|
☐ |
|
Accelerated filer |
|
☐ |
|
|
|
|
Non-accelerated filer |
|
☒ |
|
Smaller reporting company |
|
☒ |
|
|
|
|
|
|
|
|
Emerging Growth company |
|
☒ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended
transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☒